Immunic Secures $200M Upfront in Oversubscribed Private Placement, Extends Runway, and Confirms Phase 3 Data by Year-End
IMUX has more than doubled off its 52-week low of $5.062 on light trading volume (0.4× avg).
Summary
Immunic, Inc. announced its first quarter 2026 financial results and a significant corporate update. The company secured $200 million upfront in an oversubscribed private placement, with the potential for an additional $200 million, which is expected to fund operations through mid-2027 and support a planned New Drug Application (NDA) submission. This substantial capital raise, relative to the company's market capitalization, significantly de-risks its financial position. Additionally, Immunic appointed Michael A. Panzara as its new Chief Medical Officer and confirmed that top-line data from its pivotal Phase 3 ENSURE trials for vidofludimus calcium in relapsing multiple sclerosis are expected by the end of 2026. These updates provide critical clarity on the company's financial stability, leadership, and key clinical development milestones, which are highly material for a late-stage biotechnology company. Investors will now focus on the upcoming Phase 3 data readout as the next major catalyst.
At the time of this announcement, IMUX was trading at $12.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $162.1M. The 52-week trading range was $5.06 to $15.10. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: EQS.